Cargando…

Does the natural product, honokiol, have value in the battle against osimertinib resistance?

Detalles Bibliográficos
Autores principales:	Vallega, Karin A., Sun, Shi-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640904/ https://www.ncbi.nlm.nih.gov/pubmed/33195738 http://dx.doi.org/10.18632/oncoscience.517

Ejemplares similares

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Surgical Residents in the Battle Against COVID-19
por: Obaid, Oday, et al.
Publicado: (2021)

Battle of the sexes over paternity
por: Kim, Young-Joon, et al.
Publicado: (2015)

Battling COVID-19 Using Lessons Learned from 100 Years of Fighting Against Influenza
por: Zou, Xiaohui, et al.
Publicado: (2020)

The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle
por: Rybalka, Emma, et al.
Publicado: (2020)

Protecting Our Own: Equity for Employees as Hospitals Battle COVID-19
por: Maurer, Lydia R., et al.
Publicado: (2020)

Natural Compounds in the Battle against Microorganisms—Linalool
por: Mączka, Wanda, et al.
Publicado: (2022)

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo
por: Bonner, Michael Y., et al.
Publicado: (2016)

Uphill battle: The saga of hCG research that led to a paradigm shift
por: Rao, C. V.
Publicado: (2014)

COVID-19 and syndemic challenges in ‘Battling the Big Three’: HIV, TB and malaria()
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2021)

Destroying the Village in Order to Save It: Collateral Damage in the Battle Over Lyme Disease
por: Boyce, Ross M
Publicado: (2022)

Science in the Service of Patients: Lessons from the Past in the Moral Battle for the Future of Medical Education
por: Weisberg, Daniel F.
Publicado: (2014)

Value-Based Care in the Worldwide Battle Against Cancer
por: Johansen, Niloufer J, et al.
Publicado: (2017)

OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs
por: Kast, Richard E., et al.
Publicado: (2021)

The Egg and the Nucleus: A Battle for Supremacy
por: Gurdon, J. B.
Publicado: (2015)

To Battle COVID-19’s Twin Economic and Health Crises, Medicaid Needs Flexible Funding Structures for Stabilization
por: O’Mahen, Patrick N., et al.
Publicado: (2021)

Perspectives on Battling COVID-19 in Countries of Latin America and the Caribbean
por: Andrus, Jon Kim, et al.
Publicado: (2020)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu, Danlei, et al.
Publicado: (2021)

Maximum vs minimum harmonization: what to expect from the institutional and legal battles in the EU on gene editing technologies
por: Purnhagen, Kai P, et al.
Publicado: (2019)

Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature
por: Sepulveda-Falla, Diego
Publicado: (2023)

Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Nutrition: the missing link in the battle against microbial resistance?
por: Unger, Stefan A, et al.
Publicado: (2019)

Does α (+)-Thalassaemia Protect against Malaria?
por: Pasvol, Geoffrey
Publicado: (2006)

Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature
por: Ghozy, Sherief, et al.
Publicado: (2022)

MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription
por: Deng, Liang, et al.
Publicado: (2021)

The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients
por: Uprety, Dipesh, et al.
Publicado: (2018)

Synthesis of magnolol and honokiol derivatives and their effect against hepatocarcinoma cells
por: Maioli, Margherita, et al.
Publicado: (2018)

Counteracting Cisplatin-Induced Testicular Damages by Natural Polyphenol Constituent Honokiol
por: Wang, Tse-En, et al.
Publicado: (2020)

Survivin the battle against immunosuppression
por: Manuel, Edwin R., et al.
Publicado: (2012)

The Battle against Cardiogenic Shock
por: Rahamim, Eldad, et al.
Publicado: (2022)

Malaria in the horn of Africa: The ongoing battle against drug resistance
por: Platon, Lucien, et al.
Publicado: (2023)

Why have nanotechnologies been underutilized in the global uprising against the coronavirus pandemic?
por: Uskoković, Vuk
Publicado: (2020)

Bacterial Natural Product Drug Discovery for New Antibiotics: Strategies for Tackling the Problem of Antibiotic Resistance by Efficient Bioprospecting
por: Schneider, Yannik K.
Publicado: (2021)

Antineoplastic Effects of Honokiol on Melanoma
por: Guillermo-Lagae, Ruth, et al.
Publicado: (2017)

The application prospects of honokiol in dermatology
por: Li, Yao, et al.
Publicado: (2022)

Intravenous Honokiol in Drug-Resistant Cancer: Two Case Reports
por: Eliaz, Isaac, et al.
Publicado: (2020)

Exploring Possible Ways to Enhance the Potential and Use of Natural Products through Nanotechnology in the Battle against Biofilms of Foodborne Bacterial Pathogens
por: Arunachalam, Kannappan, et al.
Publicado: (2023)

Evolving paradigms for natural-product drug discovery
por: Cordell, Geoffrey A
Publicado: (2022)

Natural products are the treasure pool for antimalarial agents
por: Zhou, Bin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q6s79qqm0aakhbsjqaauiaj4ge